What: OncoMed Pharmaceuticals (OMED) is down 14% at 12:42 p.m. EDT after announcing the pricing of its secondary offering this morning.
So what: Yesterday, the development-stage biotech announced plans to raise capital through a secondary offering, and by this morning, OncoMed already had investors lined up to buy the shares. Typically, that kind of quick turnaround is a good sign that there are large investors looking to get large blocks of shares, which is easier to do in a secondary offering than on the open market.
Instead, it appears investors were quickly stepping up to buy shares because of the discount OncoMed was offering. The deal was priced at $10 per share, almost 15% lower than where it closed yesterday.
While that's not the worst discount we've seen this year, OcoMed's shares have been as high as $23.98 within the last year. Raising near that price would have diluted shareholders substantially less. As it is, OncoMed sold 5.5 million shares, adding to the 30.67 million shares the biotech already had outstanding.
OncoMed will net about $51.4 million in the deal, adding to the $171.5 million it had in the bank at the end of the second quarter. There's potential for the investment bank to sell another 825,000 shares, which could add another $8 million or so.
Now what: Secondary offerings are nothing new to biotech. It's very rare that a biotech can go from IPO to profitable without ever raising additional capital. Investors just have to hope that management raises the capital at successively higher valuations, reducing the impact of the dilution.
Rather than looking at the share price, investors should focus on the market cap of the company, because that will ultimately determine the return from here until OncoMed gets a drug on the market. Based on the new share count -- being conservative assuming the overage is also sold -- OncoMed has a market cap of about $370 million, which is actually slightly more than the approximately $359 million market cap OncoMed closed at yesterday.
OncoMed is cheaper when you subtract out the cash, referred to as the enterprise value, but since the new cash will be spent long before OncoMed is profitable, investors are rightfully discounting most of it.